Global allergy immunotherapy market is expected to show a significant growth rate during the forecast period. Allergy is hypersensitive to the body’s immune system towards several substances that include pollen, dust, and food. There are various types of allergies includes drugs, food, pollen, latex, and dust among others. As per the Food Allergy Research & Association (FARA), around 15 million people in the US have food allergies and approximately 4% of which is seen in the pediatrics and around more than 60% in adults. The introduction of new immunotherapy drugs and advancement in the treatment and medicine of allergyis the factor fueling the growth of the allergy immunotherapy market during the forecast period.
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/allergy-immunotherapy-market
The rising prevalence of allergies along with growing demand for the treatment of these diseases are motivating the key players of the allergy immunotherapy market to launch technologically advanced and cost-efficient treatment that can be affordable to the large pool of patients. The major market players are actively conducting strategic acquisitions, partnerships, and collaboration to increase their market presence and to gain a competitive edge. For instance, in April 2018, ALK had announced its partnership with Torii Pharmaceutical Co. Ltd. has agreed on a price with authorities and secured a listing on National health Insurance reimbursement for its sublingual allergy immunotherapy tablet against Japanese cedar allergy, brand name CEDAARCURE.
Browse for Full Report Description@ https://www.omrglobal.com/industry-reports/allergy-immunotherapy-market
In January 2019, Sandoz, Inc. had announced the introduction of SYMJEPI (epinephrine) 0.3 mg injection for the treatment of allergic reactions (Type 1) in the emergency including anaphylaxis, allergen immunotherapy, drugs, diagnostics testing substance, foods as well as exercise-induced anaphylaxis. The company is introducing this medicine as areasonable, affordable, single-dose and prefilled syringe alternative to epinephrine auto-injectors. In February 2018, Aimmune therapeutics, Biopharmaceutical Company developing a treatment for food allergies, introduced its phase 3 European clinical trial of AR101 for the treatment of peanut allergy that named ARTEMIS met its efficacy endpoint required by the Food and Drug Administration (FDA).
Global Allergy Immunotherapy Market- Segmentation
By Type
- Allergic Rhinitis
- Allergic Asthma
- Food Allergy
- Drug Allergy
- Others
By Treatment
- Subcutaneous Immunotherapy
- Sublingual Immunotherapy
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Global Allergy Immunotherapy Market – Segment by Region
North America
- US
- Canada
Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
- Latin America
- Middle East Africa
Company Profiles
- Aimmune Therapeutics, Inc.
- ALK-Abello A/S
- Allergopharma (A Division of Merck KGaA)
- Allergy Therapeutics PLC
- Biomay AG
- CircassiaPharmaceuticals PLC
- DBV Technologies S.A.
- Desentum Oy
- HAL Allergy Group
- Jubilant Life Sciences, Ltd.
- LetiPharma
- Merck KGaA
- Sandoz, Inc.
- Stallergenes GREER, Ltd.
- Torii Pharmaceutical Co, Ltd.
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
